Covidien Plc. (NYSE:COV) announced a new agreement for a five year $1.5 billion senior unsecured revolving credit facility, secured through subsidiary Covidien International Finance S.A.
The new agreement replaces a prior five-year senior credit facility that was slated to mature in April 2012, and the funds will be allocated for general corporate purposes, including working capital and capital expenditures.
Fluidnet Corp. appointed Benjamin Bulkley CEO in a unamimous decision by the company’s board of directors.
Founder Jeff Carlisle stepped down as chief executive to become the Portsmouth, N.H.-based IV infusion system developer’s CIO.
Before joining Fluidnet, Bulkley was COO at health IT firm Allscripts (NSDQ:MDRX) and prior to that led the global commercial operations of life science instrument Invitrogen (NSDQ:IVGN).
Fluidnet Corp. CEO Jeff Carlisle fairly bristles when he reads his company described as an IV infusion pump maker, as MassDevice did in the first version of this story published March 11.
His company’s system is so advanced compared with current infusion systems, he says, calling it a pump is just not accurate.
"To characterize this as an infusion pump company would be so misleading. We’re really taking a holistic look at the IV therapy process," Carlisle told MassDevice. "The information flow is an important as the fluid flow."
MassDevice Network
@MassDevice
LinkedIn
YouTube